BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 22521243)

  • 1. ALDH+ tumor-initiating cells exhibiting gain in NOTCH1 gene copy number have enhanced regrowth sensitivity to a γ-secretase inhibitor and irinotecan in colorectal cancer.
    Arcaroli JJ; Powell RW; Varella-Garcia M; McManus M; Tan AC; Quackenbush KS; Pitts TM; Gao D; Spreafico A; Dasari A; Touban BM; Messersmith WA
    Mol Oncol; 2012 Jun; 6(3):370-81. PubMed ID: 22521243
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tumours with elevated levels of the Notch and Wnt pathways exhibit efficacy to PF-03084014, a γ-secretase inhibitor, in a preclinical colorectal explant model.
    Arcaroli JJ; Quackenbush KS; Purkey A; Powell RW; Pitts TM; Bagby S; Tan AC; Cross B; McPhillips K; Song EK; Tai WM; Winn RA; Bikkavilli K; Vanscoyk M; Eckhardt SG; Messersmith WA
    Br J Cancer; 2013 Aug; 109(3):667-75. PubMed ID: 23868008
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differentiated human colorectal cancer cells protect tumor-initiating cells from irinotecan.
    Emmink BL; Van Houdt WJ; Vries RG; Hoogwater FJ; Govaert KM; Verheem A; Nijkamp MW; Steller EJ; Jimenez CR; Clevers H; Borel Rinkes IH; Kranenburg O
    Gastroenterology; 2011 Jul; 141(1):269-78. PubMed ID: 21459094
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The novel tankyrase inhibitor (AZ1366) enhances irinotecan activity in tumors that exhibit elevated tankyrase and irinotecan resistance.
    Quackenbush KS; Bagby S; Tai WM; Messersmith WA; Schreiber A; Greene J; Kim J; Wang G; Purkey A; Pitts TM; Nguyen A; Gao D; Blatchford P; Capasso A; Schuller AG; Eckhardt SG; Arcaroli JJ
    Oncotarget; 2016 May; 7(19):28273-85. PubMed ID: 27070088
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synergistic effect of the γ-secretase inhibitor PF-03084014 and docetaxel in breast cancer models.
    Zhang CC; Yan Z; Zong Q; Fang DD; Painter C; Zhang Q; Chen E; Lira ME; John-Baptiste A; Christensen JG
    Stem Cells Transl Med; 2013 Mar; 2(3):233-42. PubMed ID: 23408105
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A NOTCH1 gene copy number gain is a prognostic indicator of worse survival and a predictive biomarker to a Notch1 targeting antibody in colorectal cancer.
    Arcaroli JJ; Tai WM; McWilliams R; Bagby S; Blatchford PJ; Varella-Garcia M; Purkey A; Quackenbush KS; Song EK; Pitts TM; Gao D; Lieu C; McManus M; Tan AC; Zheng X; Zhang Q; Ozeck M; Olson P; Jiang ZQ; Kopetz S; Jimeno A; Keysar S; Eckhardt G; Messersmith WA
    Int J Cancer; 2016 Jan; 138(1):195-205. PubMed ID: 26152787
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting aberrant expression of Notch-1 in ALDH
    Pal D; Kolluru V; Chandrasekaran B; Baby BV; Aman M; Suman S; Sirimulla S; Sanders MA; Alatassi H; Ankem MK; Damodaran C
    Mol Carcinog; 2017 Mar; 56(3):1127-1136. PubMed ID: 27753148
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Aldehyde dehydrogenase activity selects for lung adenocarcinoma stem cells dependent on notch signaling.
    Sullivan JP; Spinola M; Dodge M; Raso MG; Behrens C; Gao B; Schuster K; Shao C; Larsen JE; Sullivan LA; Honorio S; Xie Y; Scaglioni PP; DiMaio JM; Gazdar AF; Shay JW; Wistuba II; Minna JD
    Cancer Res; 2010 Dec; 70(23):9937-48. PubMed ID: 21118965
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of the NOTCH pathway using γ-secretase inhibitor RO4929097 has limited antitumor activity in established glial tumors.
    Dantas-Barbosa C; Bergthold G; Daudigeos-Dubus E; Blockus H; Boylan JF; Ferreira C; Puget S; Abely M; Vassal G; Grill J; Geoerger B
    Anticancer Drugs; 2015 Mar; 26(3):272-83. PubMed ID: 25486598
    [TBL] [Abstract][Full Text] [Related]  

  • 10. UCN-01 enhances cytotoxicity of irinotecan in colorectal cancer stem-like cells by impairing DNA damage response.
    Signore M; Buccarelli M; Pilozzi E; De Luca G; Cappellari M; Fanciulli M; Goeman F; Melucci E; Biffoni M; Ricci-Vitiani L
    Oncotarget; 2016 Jul; 7(28):44113-44128. PubMed ID: 27286453
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PEST domain mutations in Notch receptors comprise an oncogenic driver segment in triple-negative breast cancer sensitive to a γ-secretase inhibitor.
    Wang K; Zhang Q; Li D; Ching K; Zhang C; Zheng X; Ozeck M; Shi S; Li X; Wang H; Rejto P; Christensen J; Olson P
    Clin Cancer Res; 2015 Mar; 21(6):1487-96. PubMed ID: 25564152
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Notch pathway inhibition using DAPT, a γ-secretase inhibitor (GSI), enhances the antitumor effect of cisplatin in resistant osteosarcoma.
    Dai G; Deng S; Guo W; Yu L; Yang J; Zhou S; Gao T
    Mol Carcinog; 2019 Jan; 58(1):3-18. PubMed ID: 29964327
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of gamma-secretase activity impedes uterine serous carcinoma growth in a human xenograft model.
    Groeneweg JW; Hall TR; Zhang L; Kim M; Byron VF; Tambouret R; Sathayanrayanan S; Foster R; Rueda BR; Growdon WB
    Gynecol Oncol; 2014 Jun; 133(3):607-15. PubMed ID: 24667249
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Notch1 expression predicts an unfavorable prognosis and serves as a therapeutic target of patients with neuroblastoma.
    Chang HH; Lee H; Hu MK; Tsao PN; Juan HF; Huang MC; Shih YY; Wang BJ; Jeng YM; Chang CL; Huang SF; Tsay YG; Hsieh FJ; Lin KH; Hsu WM; Liao YF
    Clin Cancer Res; 2010 Sep; 16(17):4411-20. PubMed ID: 20736329
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anti-DLL4 inhibits growth and reduces tumor-initiating cell frequency in colorectal tumors with oncogenic KRAS mutations.
    Fischer M; Yen WC; Kapoun AM; Wang M; O'Young G; Lewicki J; Gurney A; Hoey T
    Cancer Res; 2011 Mar; 71(5):1520-5. PubMed ID: 21193546
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combination of Trabectedin With Irinotecan, Leucovorin and 5-Fluorouracil Arrests Primary Colorectal Cancer in an Imageable Patient-derived Orthotopic Xenograft Mouse Model.
    Zhu G; Zhao M; Han Q; Tan Y; Sun YU; Bouvet M; Clary B; Singh SR; Ye J; Hoffman RM
    Anticancer Res; 2019 Dec; 39(12):6463-6470. PubMed ID: 31810910
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Enhanced antitumor activity of anti-epidermal growth factor receptor monoclonal antibody IMC-C225 in combination with irinotecan (CPT-11) against human colorectal tumor xenografts.
    Prewett MC; Hooper AT; Bassi R; Ellis LM; Waksal HW; Hicklin DJ
    Clin Cancer Res; 2002 May; 8(5):994-1003. PubMed ID: 12006511
    [TBL] [Abstract][Full Text] [Related]  

  • 18. TOP1 gene copy numbers in colorectal cancer samples and cell lines and their association to in vitro drug sensitivity.
    Rømer MU; Jensen NF; Nielsen SL; Müller S; Nielsen KV; Nielsen HJ; Brünner N
    Scand J Gastroenterol; 2012 Jan; 47(1):68-79. PubMed ID: 22171973
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synergistic interaction between the EGFR tyrosine kinase inhibitor gefitinib ("Iressa") and the DNA topoisomerase I inhibitor CPT-11 (irinotecan) in human colorectal cancer cells.
    Koizumi F; Kanzawa F; Ueda Y; Koh Y; Tsukiyama S; Taguchi F; Tamura T; Saijo N; Nishio K
    Int J Cancer; 2004 Jan; 108(3):464-72. PubMed ID: 14648715
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gamma-secretase complex-dependent intramembrane proteolysis of CD147 regulates the Notch1 signaling pathway in hepatocellular carcinoma.
    Yong YL; Zhang RY; Liu ZK; Wei D; Shang YK; Wu J; Zhang ZY; Li C; Chen ZN; Bian H
    J Pathol; 2019 Oct; 249(2):255-267. PubMed ID: 31215640
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.